Overview Dividends

(UTHR) United Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US91307C1027

Treprostinil, Orenitram, Unituxin, Aurora-GT, Xenografts

Biotechnology
Market Cap in USD: 22,465m

IPO / Inception: 1999-06-17
Return 12m vs S&P 500: 9.45%

EPS (Earnings per Share)

EPS CAGR: -46.55%
EPS Trend: -7.5%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 19.09%
Rev. Trend: 98.1%

Last SUE: -0.55
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	32.0%
Value at Risk 5%th	44.1%
Relative Tail Risk	-16.37%

Reward TTM
Sharpe Ratio	0.71
Alpha	23.39
CAGR/Max DD	0.70

Character TTM
Hurst Exponent	0.393
Beta	0.387
Beta Downside	0.451

Drawdowns 3y
Max DD	33.00%
Mean DD	11.93%
Median DD	12.00%

Description: UTHR United Therapeutics December 19, 2025

United Therapeutics Corporation (NASDAQ: UTHR) is a U.S. biotech that develops and commercializes therapies for chronic, life-threatening conditions, with a primary focus on pulmonary arterial hypertension (PAH) and high-risk neuroblastoma.

Its marketed portfolio includes Tyvaso (both inhaled solution via ultrasonic nebulizer and dry-powder inhaler), the treprostinil injection Remodulin, the oral treprostinil tablet Orenitram, the PDE-5 inhibitor Adcirca, the monoclonal antibody Unituxin for neuroblastoma, and the Remunity infusion pump that delivers Remodulin.

The pipeline features RemoPro (a subcutaneous treprostinil formulation), the oral PAH candidate Ralinepag, Aurora-GT gene-therapy aimed at rebuilding pulmonary vasculature, a nebulized Tyvaso formulation for idiopathic pulmonary fibrosis, and early-stage xenograft organ products.

United Therapeutics leverages strategic collaborations: a licensing deal with DEKA for a semi-disposable subcutaneous treprostinil system, a partnership with MannKind to co-develop an inhalation powder and the Dreamboat device, and a joint development agreement with Arena Pharmaceuticals on Ralinepag.

Key financial and market indicators: FY 2023 revenue reached approximately $1.2 billion, up ~12 % YoY; cash and equivalents stood at $1.5 billion, providing runway for pipeline advancement; net income was $140 million. The global PAH market is projected to exceed $6 billion by 2028, driven by an aging population and improved diagnostic rates, while overall biotech R&D spending grew 8 % YoY, underscoring a favorable funding environment for innovative therapies.

For a deeper, data-driven valuation of UTHR, you might find ValueRay’s analyst toolkit worth a quick look.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.27b TTM) > 0 and > 6% of Revenue (6% = 187.7m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA 2.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 94.22% (prev 113.5%; Δ -19.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.21 (>3.0%) and CFO 1.56b > Net Income 1.27b (YES >=105%, WARN >=100%)

Net Debt (-1.14b) to EBITDA (1.71b) ratio: -0.67 <= 3.0 (WARN <= 3.5)

Current Ratio 6.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (47.3m) change vs 12m ago -2.27% (target <= -2.0% for YES)

Gross Margin 88.59% (prev 88.94%; Δ -0.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 43.23% (prev 38.69%; Δ 4.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 69.07 (EBITDA TTM 1.71b / Interest Expense TTM 24.3m) >= 6 (WARN >= 3)

Altman Z'' 19.13

(A) 0.40 = (Total Current Assets 3.49b - Total Current Liabilities 546.3m) / Total Assets 7.35b

(B) 1.11 = Retained Earnings (Balance) 8.19b / Total Assets 7.35b

warn (B) unusual magnitude: 1.11 — check mapping/units

(D) 10.77 = Book Value of Equity 8.19b / Total Liabilities 760.9m

Total Rating: 19.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 87.85

1. Piotroski 6.50pt

2. FCF Yield 5.61%

3. FCF Margin 35.86%

4. Debt/Equity 0.05

5. Debt/Ebitda -0.67

6. ROIC - WACC (= 11.62)%

7. RoE 18.83%

8. Rev. Trend 98.07%

9. EPS Trend -7.53%

What is the price of UTHR shares?

As of January 10, 2026, the stock is trading at USD 483.23 with a total of 410,507 shares traded.
Over the past week, the price has changed by -2.72%, over one month by +1.44%, over three months by +8.50% and over the past year by +32.40%.

Is UTHR a buy, sell or hold?

United Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy UTHR.

Strong Buy: 6
Buy: 2
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the UTHR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	518.3	7.2%
Analysts Target Price	518.3	7.2%
ValueRay Target Price	581.4	20.3%

UTHR Fundamental Data Overview January 03, 2026

P/E Trailing = 18.486
P/E Forward = 15.6495
P/S = 7.1809
P/B = 3.1834
P/EG = 1.4347
Beta = 0.861
Revenue TTM = 3.13b USD
EBIT TTM = 1.68b USD
EBITDA TTM = 1.71b USD
Long Term Debt = unknown (none)
Short Term Debt = 300.0m USD (from shortTermDebt, last fiscal year)
Debt = 300.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -1.14b USD (from netDebt column, last quarter)
Enterprise Value = 20.00b USD (22.46b + Debt 300.0m - CCE 2.77b)
Interest Coverage Ratio = 69.07 (Ebit TTM 1.68b / Interest Expense TTM 24.3m)
EV/FCF = 17.82x (Enterprise Value 20.00b / FCF TTM 1.12b)
FCF Yield = 5.61% (FCF TTM 1.12b / Enterprise Value 20.00b)
FCF Margin = 35.86% (FCF TTM 1.12b / Revenue TTM 3.13b)
Net Margin = 40.65% (Net Income TTM 1.27b / Revenue TTM 3.13b)
Gross Margin = 88.59% ((Revenue TTM 3.13b - Cost of Revenue TTM 356.9m) / Revenue TTM)
Gross Margin QoQ = 87.38% (prev 89.03%)
Tobins Q-Ratio = 2.72 (Enterprise Value 20.00b / Total Assets 7.35b)
Interest Expense / Debt = 1.0% (Interest Expense 3.00m / Debt 300.0m)
Taxrate = 22.67% (99.3m / 438.0m)
NOPAT = 1.30b (EBIT 1.68b * (1 - 22.67%))
Current Ratio = 6.40 (Total Current Assets 3.49b / Total Current Liabilities 546.3m)
Debt / Equity = 0.05 (Debt 300.0m / totalStockholderEquity, last quarter 6.59b)
Debt / EBITDA = -0.67 (Net Debt -1.14b / EBITDA 1.71b)
Debt / FCF = -1.01 (Net Debt -1.14b / FCF TTM 1.12b)
Total Stockholder Equity = 6.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.57% (Net Income 1.27b / Total Assets 7.35b)
RoE = 18.83% (Net Income TTM 1.27b / Total Stockholder Equity 6.75b)
RoCE = 24.67% (EBIT 1.68b / Capital Employed (Total Assets 7.35b - Current Liab 546.3m))
RoIC = 18.87% (NOPAT 1.30b / Invested Capital 6.88b)
WACC = 7.25% (E(22.46b)/V(22.76b) * Re(7.34%) + D(300.0m)/V(22.76b) * Rd(1.0%) * (1-Tc(0.23)))
Discount Rate = 7.34% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.54%
[DCF Debug] Terminal Value 83.24% ; FCFF base≈1.03b ; Y1≈1.22b ; Y5≈1.90b
Fair Price DCF = 909.4 (EV 38.02b - Net Debt -1.14b = Equity 39.16b / Shares 43.1m; r=7.25% [WACC]; 5y FCF grow 19.75% → 2.90% )
EPS Correlation: -7.53 | EPS CAGR: -46.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.07 | Revenue CAGR: 19.09% | SUE: -0.55 | # QB: 0
EPS next Quarter (2026-03-31): EPS=7.02 | Chg30d=-0.265 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=28.49 | Chg30d=+0.000 | Revisions Net=+5 | Growth EPS=+5.1% | Growth Revenue=+5.8%

Additional Sources for UTHR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle